Literature DB >> 24357843

Primary B-cell lymphoma of the ciliary body with 360° ('ring'-like) growth pattern.

L Konstantinidis1, M Angi2, S E Coupland2, B Damato3.   

Abstract

Mesh:

Substances:

Year:  2013        PMID: 24357843      PMCID: PMC3965815          DOI: 10.1038/eye.2013.282

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  5 in total

1.  Iris involvement by lymphoma: a review of 13 cases.

Authors:  Arman Mashayekhi; Carol L Shields; Jerry A Shields
Journal:  Clin Exp Ophthalmol       Date:  2013-01-09       Impact factor: 4.207

2.  360 degrees iris-ciliary body B-cell lymphoma masquerading as post-cataract uveitis.

Authors:  Muna Ahmed; Sofia Androudi; Periklis Brazitikos; Ian Paredes; C Stephen Foster
Journal:  Semin Ophthalmol       Date:  2004 Sep-Dec       Impact factor: 1.975

Review 3.  Understanding intraocular lymphomas.

Authors:  Sarah E Coupland; Bertil Damato
Journal:  Clin Exp Ophthalmol       Date:  2008-08       Impact factor: 4.207

4.  A case of primary B-cell type non-Hodgkin lymphoma originating in the iris.

Authors:  Kazuhiro Yamada; Akira Hirata; Akira Kimura; Hidenobu Tanihara
Journal:  Am J Ophthalmol       Date:  2003-08       Impact factor: 5.258

5.  Reticulum cell sarcoma of the uvea.

Authors:  V K Raju; W R Green
Journal:  Ann Ophthalmol       Date:  1982-06
  5 in total
  3 in total

1.  A Case of Primary Central Nervous System Lymphoma with Ciliary Body Involvement.

Authors:  Meng-Da Li; Chan Zhao; Jun-Jie Ye; Hai-Yan Xu
Journal:  Chin Med J (Engl)       Date:  2016-05-20       Impact factor: 2.628

2.  Systemic diffuse large B-cell lymphoma with bilateral ciliary body involvement.

Authors:  Yu Di; Jun-Jie Ye; Bi-Lei Zhang
Journal:  Chin Med J (Engl)       Date:  2020-01       Impact factor: 2.628

3.  Case Report: Ocular Manifestations and Treatments of Ciliary Body Involvement by Lymphoma.

Authors:  Yu Di; Junjie Ye; Ruoan Han; Mengda Li; Bilei Zhang
Journal:  Front Oncol       Date:  2021-09-23       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.